A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526797-16-00

Enrollment

170

Registered

2026-09-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and overweight

Brief summary

1. Relative change in body weight from baseline (week 0) to (week 26)

Detailed description

1. Change in body weight from baseline (week 0) to (week 26), 2. AUCSS; area under the NNC0638-0355 plasma concentration-time curve at steady state from first NC0638-0355 administation to 32 weeks., 3. CmaxSS; maximum observed NNC0638-0355 plasma concentration from first NC0638-0355 administation to 32 weeks.

Interventions

DRUGPlacebo B

DRUGNNC0638-0355 A 10219

DRUGNNC0638-0355 B 10216

DRUGPlacebo A

DRUGNNC0638-0355 B 10215

DRUGNNC0638-0355 A 10218

DRUGNNC0638-0355 A 10217

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
1. Relative change in body weight from baseline (week 0) to (week 26)	—

Secondary

Measure	Time frame
1. Change in body weight from baseline (week 0) to (week 26), 2. AUCSS; area under the NNC0638-0355 plasma concentration-time curve at steady state from first NC0638-0355 administation to 32 weeks., 3. CmaxSS; maximum observed NNC0638-0355 plasma concentration from first NC0638-0355 administation to 32 weeks.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 15, 2026